Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus
Authors:
- Faouzi SalibaFSFaouzi Saliba
- Lionel RostaingLRLionel Rostaing
- Jean GugenheimJGJean Gugenheim
- François DurandFDFrançois Durand
- Sylvie RadenneSRSylvie Radenne
- Vincent LeroyVLVincent Leroy
- Martine Neau-CransacMNMartine Neau-Cransac
- Yvon CalmusYCYvon Calmus
- Ephrem SalaméESEphrem Salamé
- Georges-Philippe PageauxGPGeorges-Philippe Pageaux
- Christophe DuvouxCDChristophe Duvoux
- Naila TaguievaNTNaila Taguieva
- 1 August 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (8) , 1705-1713
Abstract
We conducted a randomized multicenter open-label trial in de novo liver transplant recipients to assess the feasibility and potential benefit of a corticosteroid (CS)-free regimen coupled with tacrolimus (Tac) and dose-intensified mycophenolate mofetil (MMF) further adjusted individually. Adult liver transplant recipients were randomized on the day of transplantation to a CS-free regimen with Tac and MMF starting at 3 g/d and dose adjusted from day 5 according to mycophenolic acid (MPA) exposure (arm A) or a regimen with CS maintained up to 6 months, Tac and fixed-dose MMF (2 g/d) (arm B). The primary end point was the proportion of patients who experienced treated biopsy-proven acute rejection (BPAR) during the first year posttransplant. One hundred eighty-seven patients were randomized, and 174 comprised the per-protocol population (87 in each arm). The primary objective of noninferiority was met: 7 patients in arm A (8%) and 8 in arm B (9%) experienced treated BPAR in the first year. Two patients in arm A (2%) and 5 in arm B (6%) lost their graft, and 12-month patient survival was similar in both arms (90.8% vs 89.8%; P = 0.86). Adverse events were comparable between arms, except for a lower incidence of de novo diabetes (19.8% vs 32.6%, P = 0.049) and a higher incidence of leukopenia less than 2000/mm (28.6% vs 9.8%; P = 0.001) and neutropenia (26.7% vs 7.9%; P < 0.001) in arm A. Mycophenolate mofetil at intensified and individually adjusted dose in combination with Tac in de novo liver transplant recipients allows CS discontinuation from day 1 posttransplant with good tolerance and very low rejection incidence.Keywords
This publication has 36 references indexed in Scilit:
- Tacrolimus-Based, Steroid-Free Regimens in Renal TransplantationTransplantation, 2012
- A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft RecipientsJournal of Transplantation, 2012
- Early Steroid Withdrawal and Optimization of Mycophenolic Acid Exposure in Kidney Transplant Recipients Receiving Mycophenolate MofetilTransplantation, 2011
- Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipientsLiver Transplantation, 2009
- Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled TrialTransplantation, 2008
- Mycophenolate Mofetil Use Is Associated with Decreased Risk of Late Acute Rejection in Adult Liver Transplant RecipientsAmerican Journal of Transplantation, 2006
- Sequential Determination of Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid in Liver Transplant Patients Treated with Mycophenolate MofetilTransplantation, 2006
- Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting PeriodsTherapeutic Drug Monitoring, 2005
- Predictive Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault Equations for Estimating Renal FunctionJournal of the American Society of Nephrology, 2005
- ERRATUMTransplantation, 1998